Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial Meeting Abstract
| Authors: | Patel, P.; Ruppert, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; Litzow, M. R.; Lin, T. L.; Foster, M. C.; Redner, R. L.; Al-Mansour, Z.; Cogle, C. R.; Boyiadzis, M. M.; Swords, R.; Collins, R. H.; Vergilio, J. A.; Heerema, N. A.; Rosenberg, L.; Yocum, A. O.; Marcus, S.; Chen, T.; Druggan, F.; Stefanos, M.; Gana, T. J.; Shoben, A. B.; Druker, B. J.; Burd, A.; Byrd, J. C.; Levine, R. L.; Mims, A. S. |
| Abstract Title: | Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398803173 |
| DOI: | 10.1182/blood-2021-149115 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 875 -- Hybrid meeting, also took place online -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work